Trump says JPMorgan Chase, Bank of America rejected him as a customer
President Donald Trump said Tuesday that the two largest U.S. banks rejected him as a bank customer, reviving claims of debanking against conservatives.
Posts by CNBC (old posts, page 81)
AI is already impacting the labor market, starting with young tech workers, Goldman economist says
Unemployment rates among tech workers between 20 and 30 years old jumped by 3 percentage points since the start of this year, said Goldman Sachs' Joseph Briggs.
S&P 500 struggles to make it two wins in row — plus, a portfolio name leads the M&A race
Every weekday, the Investing Club releases the Homestretch; an actionable afternoon update just in time for the last hour of trading.
Roku launches ad-free streaming service, Howdy, for $2.99 a month
The service runs alongside the free, ad-supported Roku Channel, and adds to Roku's growing content lineup.
Russia's economy 'stinks,' Trump says, and lower oil prices will stop its war machine
"Putin will stop killing people if you get energy down another $10 a barrel. He's going to have no choice because his economy stinks," Trump said Tuesday.
Trump says pharma tariffs could eventually reach up to 250%
Trump said he will initially impose a "small tariff" on pharmaceuticals, but then in a year to a year and a half, he will raise that rate to 150% and then 250%.
Coterra's earnings beat doesn't change the big picture for the oil producer
Oil and gas prices haven't been on Coterra's side, making it a difficult stock to own.
Pfizer hikes 2025 profit outlook on cost cuts, strong quarterly results
The results come as Pfizer and other drugmakers grapple with Trump's calls to lower U.S. drug prices and brace for his planned tariffs on pharmaceuticals.
Pfizer hikes 2025 profit outlook on cost cuts, strong quarterly results
The results come as Pfizer and other drugmakers grapple with Trump's calls to lower U.S. drug prices and brace for his planned tariffs on pharmaceuticals.
We're raising our DuPont price target after a beat and raise and ahead of breakup
Given the upcoming break-up catalyst, along with a strong quarter and full-year guidance raise, we're reiterating our buy-equivalent 1 rating.